#THRV
Thryv Therapeutics to Present at UBS Global Biopharma Conference in London, Showcasing New Innovations#London#United_Kingdom#UBS_Conference#Thryv_Therapeutics#THRV-1268
Thryv Therapeutics to Present at UBS Global Biopharma Conference in London, Showcasing New Innovations
Thryv Therapeutics is gearing up for the UBS Global Biopharma Conference in London, where they will unveil updates on their cutting-edge therapies for heart diseases.
third-news.com
November 12, 2026 at 4:36 PM
Now live in JACC: Heart Failure: human genetic, preclinical and clinical evidence supporting SGK1 as a validated target and THRV-1268 as a potential first-in-class therapy for HFrEF.

Open-access paper: https://bit.ly/3T6ddMb
Full release: https://bit.ly/46oZrYo

#HFrEF #SGK1
September 15, 2026 at 3:47 PM
【バシャール】パワースポット信仰は危険|ボルテックスの真実|セドナやシャスタの正体 #bashar #スピリチュアル #パラレルリアリティ #チャネリング #オープンコンタクト #ピラミッド #聖地
YouTube video by パラレルリアリティ | 眠れる宇宙の法則
www.youtube.com
September 12, 2026 at 1:40 PM
Estamos ao vivo na gravação do Reloading 486!

www.youtube.com/watch?v=ThRv...
Reloading #486 – NOTÍCIAS DA SEMANA (Gravação AO VIVO)
YouTube video by ReloadingBR Podcast
www.youtube.com
November 27, 2024 at 9:58 PM
Die Theologische Revue über das Buch "Menschenwürde und Existenzminimum", das Jens-Peter Brune und ich herausgegeben haben.
ejournals.uni-muenster.de/thrv/article...
July 21, 2026 at 9:37 AM
Final stop on the spring circuit: Jefferies Global Healthcare Conference 2026.

📅 June 2–4 📍 New York 🤝 1:1 investor meetings

Updates on our SGK1 platform: Wave II Phase 2/3 in LQTS, Fast Track for THRV-1268, Phase 2a in HFrEF on deck.

#JefferiesHealthcare #SGK1
June 1, 2026 at 3:35 PM
Next stop: RBC. Thryv presents at the RBC Capital Markets Global Healthcare Conference.

📅 Tue, May 19 · 10:30 AM ET 📍 NYC

Latest on our SGK1 platform: Wave II Phase 2/3 in LQTS, Fast Track for THRV-1268, Phase 2a in HFrEF on deck.

1:1s: admin@thryvtrx.com

#SGK1 #Biotech
May 15, 2026 at 12:00 PM
Thryv Therapeutics is heading to UBS Global Healthcare Conference 2026.

📅 Mon, May 18 · 1:15 PM ET 📍 NYC

We'll share updates on our SGK1 pipeline: Phase 2/3 in LQTS, Fast Track for THRV-1268, Phase 2a in HFrEF coming.

Meet: admin@thryvtrx.com

#UBSHealthcare #SGK1
May 14, 2026 at 12:00 PM
Our wave is moving.
🟢 First patient enrolled in Wave II (Phase 2/3, LQTS Type 2).
🟢 FDA Fast Track Designation granted for THRV-1268. Initial data expected Q4 2026.

Full PR: https://bit.ly/4vGYlCw

#LQTS #RareDisease #FastTrack #Cardiology #Biotech
April 22, 2026 at 2:04 PM
We’re pleased to share positive Phase 1 results for THRV-1268, showing clear target engagement and QTcF shortening in obese participants. These data support SGK1 inhibition in cardiometabolic disease & HF. Phase 2a Aspire-HF planned for 2026.
🔗 www.newswire.ca/news-release...
December 17, 2025 at 2:28 PM
We’re thrilled to welcome Matt Killeen, PhD, as CBO at Thryv!
With deep expertise in cardiovascular & genetic diseases, Matt will help drive our BD strategy and advance THRV-1268 toward Phase 2/3.

Link: loom.ly/4kCC3Oo

#SGK1 #Cardiology #Biotech #LQTS #HeartFailure #AFib
December 2, 2025 at 2:23 PM
We’re excited to welcome Amy Rudolph, PhD, to Thryv Therapeutics’ Board! Her medical affairs and cardiovascular drug development expertise will help advance THRV-1268 and our SGK1 platform.

Read more: www.newswire.ca/news-release...

#SGK1 #Cardiology #Biotech #LQTS #HeartFailure #AFib
November 19, 2025 at 3:48 PM
Thryv Therapeutics will present 3 moderated e-posters at #AHA25 on THRV-1268, part of our SGK1 inhibitor portfolio targeting heart failure & cardiac remodeling.

📍 Nov 8–10 | New Orleans

Read more: loom.ly/gXgaJEQ
#CardioResearch #HeartFailure
November 5, 2025 at 2:59 PM
With FDA IND clearance and investor backing, Thryv is advancing THRV-1268, our lead SGK1 inhibitor, into Phase 2/3 for Long QT Syndrome—bringing us closer to the first approved therapy for people with LQTS.

👉 loom.ly/tZj96M8

#SGK1 #LQTS #Biotech
September 17, 2025 at 6:53 PM
📣 We’re headed to #ESCCongress! Excited to share compelling new preclinical results on our lead SGK1 inhibitor, THRV-1268.

🗓️ Aug 30 – Heart Failure | Dr. Saumya Das
🗓️ Aug 31 – LQTS | Dr. Simona Casini

Details 👉 loom.ly/LPHc97A
#SGK1 #Cardiology
August 26, 2025 at 3:29 PM
Marianne Heimbach-Steins bespricht lesenswert den von Jens Peter Brune und Wolfgang Strengmann-Kuhn @strengmann-kuhn.de herausgegebenen Band "Menschenwürde und Existenzminimum" ejournals.uni-muenster.de/thrv/article...
Anzeige von Brune, Jens Peter/Strengmann-Kuhn, Wolfgang (Hg.): Menschenwürde und Existenzminimum
ejournals.uni-muenster.de
July 21, 2026 at 6:34 PM
Good. The government must follow the independent advice.
After all, they say it's all thrv fo gor their own pay rises.🙄
April 28, 2025 at 3:33 PM
Thryv Therapeutics Secures FDA Approval for THRV-1268 to Combat Long QT Syndrome#Canada#Montreal#Thryv_Therapeutics#Long_QT_Syndrome#THRV-1268
Thryv Therapeutics Secures FDA Approval for THRV-1268 to Combat Long QT Syndrome
Thryv Therapeutics has received FDA IND clearance for THRV-1268, a significant step towards addressing Long QT Syndrome with upcoming clinical trials.
third-news.com
September 17, 2025 at 6:51 PM